Visante: Reconsidering Drug Prices, Rebates, and PBMs
August 15, 2018
The Visante study highlights top selling Medicare Part D brand-name drugs with steady price increases and no change in rebate...
Filter by:
Choose a Topic
Filter by Year:Clear Filters- Research
- Biosimilars
- Drug Abuse Prevention
- Drug Adherence Programs
- Drug Cost Management
- Drug Coupons & Assistance Programs
- Drug Coverage Mandates
- Drug Price Negotiations & Rebates
- Employers, Unions, & Insurers
- FEHB Program
- Formulary Design
- Fraud, Waste, & Abuse
- Generic Drug Utilization
- Health Insurance Marketplace (ACA)
- Home Delivery of Drugs
- Medicaid
- Medicare Part D
- Patient Cost Sharing
- Pharmacy Networks
- Pharmacy Reimbursement & Contracting
- REMS Management
- Specialty Benefit Design
- Specialty Pharmacies
- Specialty Pharmacy Networks
- TRICARE
PCMA Comments on Administration’s Blueprint on Drug Pricing
July 16, 2018
Click here to read PCMA’s comments on the Blueprint...
Oliver Wyman Study: Premium Impact of Removing Manufacturer Rebates from the Medicare Part D Program
July 16, 2018
In 2018, more than 44 million seniors and people with disabilities are expected to be enrolled in Medicare Part D....
Legal Analysis: Antitrust Considerations of Proposals to Limit Rebates
July 15, 2018
A legal analysis raises significant concerns as to drug manufacturers’ ability to offer upfront discounts under current antitrust case law....
New PCMA Ad: “Just Cut the Price”
June 25, 2018
America’s Pharmacy Benefit Managers (PBMs) agree with the Administration and Patients. The most direct way to reduce costs and improve...
Insulins: Prices, Rebates, and Other Factors Influencing Costs
May 08, 2018
Along with setting high prices for insulin products, drug manufacturers’ pricing strategies, including the use of multi-drug combination products to...
Mandatory Electronic Prescribing of Controlled Substances (EPCS) Can Help Combat the Opioid Crisis
April 04, 2018
According to government estimates, the opioid epidemic has reached crisis proportions, and now costs the US more than $500 billion...
PCMA Member Survey: The Impact of POS Rebates and POS Pharmacy DIR
March 27, 2018
The Pharmaceutical Care Management Association (PCMA) had an independent third party conduct a survey of its members to assess the...
Milliman Analysis: Medicare Part D Program Characteristics that Affect Plan Sponsor Gain/Loss Margin
March 16, 2018
The Medicare Part D program has regulatory requirements and competitive dynamics that affect plan sponsor gain/(loss) margin. The Pharmaceutical Care...
Increased Costs Associated With Proposed State Legislation Impacting PBM Tools
February 27, 2018
Visante was commissioned by the Pharmaceutical Care Management Association (PCMA) to estimate the potential cost impact of four types of...
Economic Impact of CMS’ Proposed Any Willing Pharmacy Policy
January 15, 2018
In its Notice of Proposed Rulemaking for 2019, the Centers for Medicare and Medicaid Services (CMS) has proposed what it...
Some Common Sense Solutions to the Opioid Crisis
November 07, 2017
The Pharmaceutical Care Management Association (PCMA) has outlined solutions that would help assure people receive opioid prescriptions only when medically...